Anticoagulation and Antiplatelet Therapy
Introduction to Therapy
- The American College of Cardiology recommends dual therapy with apixaban plus a single antiplatelet agent (preferably clopidogrel) over triple therapy to reduce bleeding risk while maintaining efficacy for preventing thrombotic events in patients requiring both anticoagulation and antiplatelet therapy 1
Patient-Specific Recommendations
- For patients with no history of acute coronary syndrome (ACS) and no prior revascularization, the American College of Cardiology recommends stopping aspirin completely and using apixaban alone 1
- For patients with prior percutaneous coronary intervention (PCI), the American College of Cardiology recommends the following:
- For patients with prior coronary artery bypass grafting (CABG), the American College of Cardiology recommends the following:
- For patients less than 12 months since ACS, the American College of Cardiology recommends stopping aspirin, continuing a P2Y12 inhibitor, and starting a DOAC 1
- For patients more than 12 months since ACS, the American College of Cardiology recommends stopping all antiplatelet therapy and starting a DOAC alone 1
- For patients with prior Transient Ischemic Attack (TIA) or stroke, the American College of Cardiology recommends stopping all antiplatelet therapy and starting a DOAC when safe from hemorrhagic transformation risk 1
Dosing and Administration
- The standard dose of apixaban is 5mg twice daily 1
- A reduced dose of 2.5mg twice daily is recommended for patients who meet at least 2 of the following criteria: age 80 years or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher 1
Minimizing Bleeding Risk
- Triple therapy (apixaban + dual antiplatelet therapy) should be avoided or minimized in duration whenever possible 1
- Radial access is preferred for PCI procedures to minimize bleeding risk 1
- Proton pump inhibitors should be considered for patients on combination therapy to reduce gastrointestinal bleeding risk 1
- The combination of antiplatelet therapy with anticoagulation significantly increases bleeding risk, and minimizing concurrent antiplatelet therapy is recommended to reduce bleeding risk 1
- The American College of Cardiology advises against continuing dual antiplatelet therapy with a DOAC unless specifically indicated, as this significantly increases bleeding risk 1
Management of Bleeding
- For patients who develop major bleeding, appropriate measures should be initiated to control bleeding, including consideration of reversal agents if necessary 1
Follow-Up and Reassessment
- Reassess the need for continued antiplatelet therapy at each follow-up visit 1
- The American College of Cardiology recommends regular monitoring for signs of bleeding, as even dual therapy carries increased bleeding risk compared to single therapy 1
- The American College of Cardiology recommends reassessing the need for continued antiplatelet therapy regularly, particularly once 12 months have passed since the ACS event, and considering discontinuing all antiplatelet therapy if more than 12 months since ACS 1